These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Reductions in glucosylsphingosine (lyso-Gb1) in treatment-naïve and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease: Data from phase 3 clinical trials. Elstein D; Mellgard B; Dinh Q; Lan L; Qiu Y; Cozma C; Eichler S; Böttcher T; Zimran A Mol Genet Metab; 2017 Sep; 122(1-2):113-120. PubMed ID: 28851512 [TBL] [Abstract][Full Text] [Related]
7. An observational study to investigate the relationship between plasma glucosylsphingosine (lyso-Gb1) concentration and treatment outcomes of patients with Gaucher disease in Japan. Ida H; Watanabe Y; Sagara R; Inoue Y; Fernandez J Orphanet J Rare Dis; 2022 Nov; 17(1):401. PubMed ID: 36329499 [TBL] [Abstract][Full Text] [Related]
8. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry. El-Beshlawy A; Tylki-Szymanska A; Vellodi A; Belmatoug N; Grabowski GA; Kolodny EH; Batista JL; Cox GF; Mistry PK Mol Genet Metab; 2017; 120(1-2):47-56. PubMed ID: 28040394 [TBL] [Abstract][Full Text] [Related]
9. Venglustat, an orally administered glucosylceramide synthase inhibitor: Assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study. Deegan PB; Goker-Alpan O; Geberhiwot T; Hopkin RJ; Lukina E; Tylki-Szymanska A; Zaher A; Sensinger C; Gaemers SJM; Modur V; Thurberg BL; Sharma J; Najafian B; Mauer M; DasMahapatra P; Wilcox WR; Germain DP Mol Genet Metab; 2023 Feb; 138(2):106963. PubMed ID: 36481125 [TBL] [Abstract][Full Text] [Related]
10. Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits. Sun Y; Liou B; Ran H; Skelton MR; Williams MT; Vorhees CV; Kitatani K; Hannun YA; Witte DP; Xu YH; Grabowski GA Hum Mol Genet; 2010 Mar; 19(6):1088-97. PubMed ID: 20047948 [TBL] [Abstract][Full Text] [Related]
11. Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. Dekker N; van Dussen L; Hollak CE; Overkleeft H; Scheij S; Ghauharali K; van Breemen MJ; Ferraz MJ; Groener JE; Maas M; Wijburg FA; Speijer D; Tylki-Szymanska A; Mistry PK; Boot RG; Aerts JM Blood; 2011 Oct; 118(16):e118-27. PubMed ID: 21868580 [TBL] [Abstract][Full Text] [Related]
13. Optimization of Eliglustat-Based Glucosylceramide Synthase Inhibitors as Substrate Reduction Therapy for Gaucher Disease Type 3. Wilson MW; Shu L; Hinkovska-Galcheva V; Jin Y; Rajeswaran W; Abe A; Zhao T; Luo R; Wang L; Wen B; Liou B; Fannin V; Sun D; Sun Y; Shayman JA; Larsen SD ACS Chem Neurosci; 2020 Oct; 11(20):3464-3473. PubMed ID: 33035424 [TBL] [Abstract][Full Text] [Related]
14. Velaglucerase alfa for the management of type 1 Gaucher disease. Morris JL Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444 [TBL] [Abstract][Full Text] [Related]
15. Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease. Pastores GM Curr Opin Investig Drugs; 2010 Apr; 11(4):472-8. PubMed ID: 20336596 [TBL] [Abstract][Full Text] [Related]
16. Plasma glucosylsphingosine correlations with baseline disease burden and response to eliglustat in two clinical trials of previously untreated adults with Gaucher disease type 1. Peterschmitt MJ; Foster MC; Ji AJ; Zajdel MB; Cox GF Mol Genet Metab; 2023 Mar; 138(3):107527. PubMed ID: 36739645 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, Safety, and Tolerability of Single-Dose Orally Administered Venglustat in Healthy Chinese Volunteers. Li Y; Li Y; Li L; Xue W; Xin K; Wang T; Shi A Clin Drug Investig; 2023 Jun; 43(6):413-420. PubMed ID: 37269489 [TBL] [Abstract][Full Text] [Related]
18. Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults. Mistry PK; Weinreb NJ; Kaplan P; Cole JA; Gwosdow AR; Hangartner T Blood Cells Mol Dis; 2011 Jan; 46(1):66-72. PubMed ID: 21112800 [TBL] [Abstract][Full Text] [Related]